Stability Prediction for Mutations in the Cytosolic Domains of Cystic Fibrosis Transmembrane Conductance Regulator
- PMID: 33720715
- PMCID: PMC10230551
- DOI: 10.1021/acs.jcim.0c01207
Stability Prediction for Mutations in the Cytosolic Domains of Cystic Fibrosis Transmembrane Conductance Regulator
Abstract
Cystic Fibrosis (CF) is caused by mutations to the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) chloride channel. CFTR is composed of two membrane spanning domains, two cytosolic nucleotide-binding domains (NBD1 and NBD2) and a largely unstructured R-domain. Multiple CF-causing mutations reside in the NBDs and some are known to compromise the stability of these domains. The ability to predict the effect of mutations on the stability of the cytosolic domains of CFTR and to shed light on the mechanisms by which they exert their effect is therefore important in CF research. With this in mind, we have predicted the effect on domain stability of 59 mutations in NBD1 and NBD2 using 15 different algorithms and evaluated their performances via comparison to experimental data using several metrics including the correct classification rate (CCR), and the squared Pearson correlation (R2) and Spearman's correlation (ρ) calculated between the experimental ΔTm values and the computationally predicted ΔΔG values. Overall, the best results were obtained with FoldX and Rosetta. For NBD1 (35 mutations), FoldX provided R2 and ρ values of 0.64 and -0.71, respectively, with an 86% correct classification rate (CCR). For NBD2 (24 mutations), FoldX R2, ρ, and CCR were 0.51, -0.73, and 75%, respectively. Application of the Rosetta high-resolution protocol (Rosetta_hrp) to NBD1 yielded R2, ρ, and CCR of 0.64, -0.75, and 69%, respectively, and for NBD2 yielded R2, ρ, and CCR of 0.29, -0.27, and 50%, respectively. The corresponding numbers for the Rosetta's low-resolution protocol (Rosetta_lrp) were R2 = 0.47, ρ = -0.69, and CCR = 69% for NBD1 and R2 = 0.27, ρ = -0.24, and CCR = 63% for NBD2. For NBD1, both algorithms suggest that destabilizing mutations suffer from destabilizing vdW clashes, whereas stabilizing mutations benefit from favorable H-bond interactions. Two triple consensus approaches based on FoldX, Rosetta_lpr, and Rosetta_hpr were attempted using either "majority-voting" or "all-voting". The all-voting consensus outperformed the individual predictors, albeit on a smaller data set. In summary, our results suggest that the effect of mutations on the stability of CFTR's NBDs could be largely predicted. Since NBDs are common to all ABC transporters, these results may find use in predicting the effect and mechanism of the action of multiple disease-causing mutations in other proteins.
Conflict of interest statement
CONFLICT OF INTEREST
The authors declare no conflict of interest and do not endorse any program.
Figures







Similar articles
-
Stabilization of a nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator yields insight into disease-causing mutations.J Biol Chem. 2017 Aug 25;292(34):14147-14164. doi: 10.1074/jbc.M116.772335. Epub 2017 Jun 27. J Biol Chem. 2017. PMID: 28655774 Free PMC article.
-
The two ATP binding sites of cystic fibrosis transmembrane conductance regulator (CFTR) play distinct roles in gating kinetics and energetics.J Gen Physiol. 2006 Oct;128(4):413-22. doi: 10.1085/jgp.200609622. Epub 2006 Sep 11. J Gen Physiol. 2006. PMID: 16966475 Free PMC article.
-
Disease-relevant mutations alter amino acid co-evolution networks in the second nucleotide binding domain of CFTR.PLoS One. 2020 Jan 24;15(1):e0227668. doi: 10.1371/journal.pone.0227668. eCollection 2020. PLoS One. 2020. PMID: 31978131 Free PMC article.
-
Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability.Cold Spring Harb Perspect Med. 2013 Mar 1;3(3):a009522. doi: 10.1101/cshperspect.a009522. Cold Spring Harb Perspect Med. 2013. PMID: 23457292 Free PMC article. Review.
-
The interactome of cystic fibrosis transmembrane conductance regulator and its role in male fertility: A critical review.J Cell Physiol. 2024 Dec;239(12):e31422. doi: 10.1002/jcp.31422. Epub 2024 Sep 26. J Cell Physiol. 2024. PMID: 39324358 Review.
Cited by
-
Rescue of Rare CFTR Trafficking Mutants Highlights a Structural Location-Dependent Pattern for Correction.Int J Mol Sci. 2023 Feb 6;24(4):3211. doi: 10.3390/ijms24043211. Int J Mol Sci. 2023. PMID: 36834620 Free PMC article.
-
S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy in vivo and in vitro in matched pediatric patient-derived cell models.Front Pediatr. 2022 Nov 16;10:1062766. doi: 10.3389/fped.2022.1062766. eCollection 2022. Front Pediatr. 2022. PMID: 36467478 Free PMC article.
-
Structural Comparative Modeling of Multi-Domain F508del CFTR.Biomolecules. 2022 Mar 18;12(3):471. doi: 10.3390/biom12030471. Biomolecules. 2022. PMID: 35327663 Free PMC article.
-
ATP-dependent thermoring basis for the heat unfolding of the first nucleotide-binding domain isolated from human CFTR.Res Sq [Preprint]. 2024 Nov 21:rs.3.rs-5479740. doi: 10.21203/rs.3.rs-5479740/v1. Res Sq. 2024. PMID: 39606474 Free PMC article. Preprint.
-
Triangulating variation in the population to define mechanisms for precision management of genetic disease.Structure. 2022 Aug 4;30(8):1190-1207.e5. doi: 10.1016/j.str.2022.05.011. Epub 2022 Jun 16. Structure. 2022. PMID: 35714602 Free PMC article.
References
-
- Veit G; Avramescu RG; Chiang AN; Houck SA; Cai Z; Peters KW; Hong JS; Pollard HB; Guggino WB; Balch WE; Skach WR; Cutting GR; Frizzell RA; Sheppard DN; Cyr DM; Sorscher EJ; Brodsky JL; Lukacs GL From CFTR Biology toward Combinatorial Pharmacotherapy: Expanded Classification of Cystic Fibrosis Mutations. Mol. Biol. Cell 2016, 27, 424–433. 10.1091/mbc.e14-04-0935. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous